Newsroom

JERSEY CITY, NEW JERSEY--(BUSINESS WIRE)--Organon a annoncé aujourd’hui avoir conclu un accord avec Daiichi Sankyo Europe pour commercialiser Nilemdo® (acide bempédoïque) en France, au Danemark, en Islande, en Suède, en Finlande et en Norvège. Nilemdo® est un nouveau médicament, premier de sa catégorie, indiqué pour les patients présentant un taux de cholestérol élevé et un risque de maladie cardiovasculaire. Il offre un traitement alternatif aux patients qui ne peuvent pas être traités efficac...

NOVA YORK & LONDRES & SYDNEY--(BUSINESS WIRE)--A Sodali & Co (a "empresa" ou "Sodali"), empresa líder global em consultoria de stakeholders focada no mercado de capitais, tem o prazer de anunciar quatro nomeações para sua Equipe de Liderança Executiva (ELT), sob a direção do CEO Andrew Benett. Esses novos cargos de liderança fortalecerão a capacidade da Sodali de responder às necessidades em constante evolução de seus clientes, oferecendo um conjunto integrado de serviços de consultoria em...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Vandaag maakte Organon bekend dat het bedrijf een akkoord heeft gesloten met Daiichi Sankyo Europe voor de commercialisering van Nilemdo® (bempedoïnezuur) in Frankrijk, Denemarken, IJsland, Zweden, Finland en Noorwegen. Nilemdo® is een nieuw geneesmiddel van topkwaliteit, aangewezen voor patiënten met een hoge cholesterol en met risico voor cardiovasculaire aandoeningen. Het biedt een alternatieve behandeling voor patiënten die niet doeltreffend met statines...

TACOMA, Wash.--(BUSINESS WIRE)--MILGARD Windows and Doors, a manufacturer of vinyl, fiberglass, and aluminum windows and patio doors, and part of the MITER Brands™ portfolio, recently announced it has completed a significant renovation of its fiberglass window and door production facility in Tacoma, Washington, to drive innovation in 2026. After removing all existing assets and refurbishing the entire 150,000-square-foot facility, MILGARD installed state-of-the-art equipment to support several...

DUBLIN--(BUSINESS WIRE)--The "Valeo 2022-2025 Labor & Employment Law Firm Hourly Rate Report" has been added to ResearchAndMarkets.com's offering. The Valeo 2022 – 2025 Labor & Employment Law Firm Hourly Rate Report details the average hourly rates of Attorneys and Support Staff at law firms practicing Labor & Employment in the AMLAW 200 and smaller (by annual revenue) firms. Using state of the art software, AI and expert legal research, the Valeo Legal Pricing Platform identifies,...

DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence Writing Assistant Software - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Artificial Intelligence Writing Assistant Software was valued at US$2.3 Billion in 2024 and is projected to reach US$8.3 Billion by 2030, growing at a CAGR of 24.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed...

NEW YORK & LONDON & SYDNEY--(BUSINESS WIRE)--Sodali & Co (das „Unternehmen“ oder „Sodali“), das führende globale Stakeholder-Beratungsunternehmen mit Schwerpunkt auf Kapitalmärkten, freut sich, vier Ernennungen für sein Executive Leadership Team (ELT) unter der Leitung von Chief Executive Officer Andrew Benett verkünden zu dürfen. Diese neu geschaffenen leitenden Positionen werden Sodalis Fähigkeit stärken, den sich wandelnden Bedürfnissen seiner Kunden mit einem integrierten Angebot an Ber...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon oggi ha annunciato la sigla di un accordo con Daiichi Sankyo Europe relativo alla commercializzazione di Nilemdo® (acido bempedoico) in Francia, Danimarca, Islanda, Svezia, Finlandia e Norvegia. Nilemdo® è un nuovo farmaco first in class indicato nei pazienti ipercolesterolemici e a rischio cardiovascolare, e rappresenta una terapia alternativa per i pazienti che non possono essere trattati efficacemente con le statine.ii "Questa collaborazione...

JERSEY CITY, Nueva Jersey--(BUSINESS WIRE)--Organon acaba de anunciar la firma de un acuerdo con Daiichi Sankyo Europe para comercializar Nilemdo® (ácido bempedóico) en Francia, Dinamarca, Islandia, Suecia, Finlandia y Noruega. Nilemdo® es un nuevo fármaco, el primero de este tipo, indicado para pacientes con colesterol alto y riesgo de padecer enfermedades cardiovasculares. Supone un tratamiento alternativo para pacientes que no puedan ser tratados eficazmente con estatinasii. «Esta colaboraci...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon gab heute bekannt, dass es eine Vereinbarung mit Daiichi Sankyo Europe über die Vermarktung von Nilemdo® (Bempedoinsäure) in Frankreich, Dänemark, Island, Schweden, Finnland und Norwegen geschlossen hat. Nilemdo® ist ein neues, erstklassiges Medikament, das für Patienten mit hohem Cholesterinspiegel und Herz-Kreislauf-Risiko indiziert ist. Es bietet eine alternative Behandlung für Patienten, die mit Statinen nicht wirksam behandelt werden können...